Deutsche Bank AG Has $6.83 Million Position in Alkermes plc $ALKS

Key Points

• Deutsche Bank AG reduced its holdings in Alkermes plc by 7.9% in Q1, now owning 206,835 shares valued at approximately $6.83 million after selling 17,835 shares.
• Several large investors increased their stakes in Alkermes, with RTW Investments LP boosting its position by 13.6% and Nuveen Asset Management lifting its stake by 109.5% in the fourth quarter.
• Alkermes reported a positive earnings performance with an EPS of $0.52, exceeding analyst estimates, and had a revenue of $390.66 million, which was significantly higher than the consensus estimate of $343.20 million.

Deutsche Bank AG lowered its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 7.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 206,835 shares of the company's stock after selling 17,835 shares during the quarter. Deutsche Bank AG owned about 0.13% of Alkermes worth $6,830,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. USA Financial Formulas bought a new position in Alkermes in the first quarter valued at approximately $49,000. Fifth Third Bancorp lifted its stake in Alkermes by 54.4% in the first quarter. Fifth Third Bancorp now owns 1,479 shares of the company's stock valued at $49,000 after buying an additional 521 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Alkermes in the fourth quarter valued at approximately $98,000. GAMMA Investing LLC lifted its stake in Alkermes by 31.9% in the first quarter. GAMMA Investing LLC now owns 5,396 shares of the company's stock valued at $178,000 after buying an additional 1,305 shares in the last quarter. Finally, Farringdon Capital Ltd. bought a new stake in shares of Alkermes in the fourth quarter worth $204,000. Institutional investors own 95.21% of the company's stock.

Insider Activity at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $31.09, for a total value of $103,654.06. Following the transaction, the senior vice president directly owned 86,208 shares in the company, valued at $2,680,206.72. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $45.00 price objective on shares of Alkermes in a research report on Tuesday, July 29th. Robert W. Baird boosted their price objective on shares of Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Royal Bank Of Canada boosted their price objective on shares of Alkermes from $40.00 to $42.00 and gave the stock a "sector perform" rating in a research report on Wednesday, July 30th. Cantor Fitzgerald raised shares of Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Alkermes in a research report on Tuesday, July 15th. They issued a "buy" rating and a $43.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Alkermes presently has an average rating of "Moderate Buy" and an average price target of $41.08.

Alkermes Stock Performance

ALKS traded up $0.12 during trading on Thursday, reaching $29.09. 50,205 shares of the stock were exchanged, compared to its average volume of 1,754,774. The stock has a market cap of $4.80 billion, a P/E ratio of 13.97, a price-to-earnings-growth ratio of 1.65 and a beta of 0.47. Alkermes plc has a twelve month low of $25.56 and a twelve month high of $36.45. The stock's 50 day moving average price is $28.38 and its two-hundred day moving average price is $30.49.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.42 by $0.10. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The business had revenue of $390.66 million for the quarter, compared to the consensus estimate of $343.20 million. During the same period in the previous year, the company earned $1.16 earnings per share. The firm's revenue for the quarter was down 2.1% on a year-over-year basis. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. Equities research analysts predict that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.